Prostate carcinoma presentation, diagnosis, and staging
dc.contributor.author | Miller, David C. | en_US |
dc.contributor.author | Hafez, Khaled S. | en_US |
dc.contributor.author | Stewart, Andrew K. | en_US |
dc.contributor.author | Montie, James E. | en_US |
dc.contributor.author | Wei, John T. | en_US |
dc.date.accessioned | 2006-04-19T13:31:37Z | |
dc.date.available | 2006-04-19T13:31:37Z | |
dc.date.issued | 2003-09-15 | en_US |
dc.identifier.citation | Miller, David C.; Hafez, Khaled S.; Stewart, Andrew; Montie, James E.; Wei, John T. (2003)."Prostate carcinoma presentation, diagnosis, and staging." Cancer 98(6): 1169-1178. <http://hdl.handle.net/2027.42/34379> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34379 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12973840&dopt=citation | en_US |
dc.description.abstract | BACKGROUND Based on the 1998 Patient Care Evaluation (PCE) from the American College of Surgeons National Cancer Data Base (NCDB), the authors described contemporary nationwide patterns of prostate carcinoma presentation, diagnosis, and staging. METHODS The authors reviewed 54,212 cases from the 1998 PCE. Demographics, presenting signs and symptoms, tumor characteristics, prostate biopsy techniques, and use of staging modalities were evaluated. RESULTS The mean age of patients in the sample was 68 years. Among patients with available data, 87.5% had a prostate specific antigen (PSA) level of 4 ng/mL or higher, 83.1% had American Joint Committee on Cancer (AJCC) Stage I–II lesions, 80.2% had well or moderately differentiated cancers, and 68.7% of newly diagnosed patients were asymptomatic. Compared with symptomatic patients, asymptomatic patients were more likely to have localized disease (84.6% vs. 78.2%, P < 0.01) and well or moderately differentiated tumors (82.2% vs. 74.6%, P < 0.01). Transrectal ultrasound-guided prostate biopsy was the most common method of tissue confirmation (45.4%). Radionuclide bone scintigraphy was the most frequently employed staging modality (48.7%). Use of various staging evaluations was more frequent among patients at increased risk for disseminated disease (PSA > 10 ng/mL and/or high-grade tumors) versus patients at lower risk (PSA ≤ 10 and low to moderate-grade tumors) for metastatic disease ( P < 0.005). CONCLUSIONS Most newly diagnosed patients with prostate carcinoma are asymptomatic and have moderately differentiated and organ-confined disease. Compared with symptomatic patients, tumors in asymptomatic men are associated with lower pretreatment PSA levels, AJCC stage, and tumor grade. Selective use of staging evaluations, based on risk of metastatic disease, may be relatively uncommon. The NCDB remains a unique and rich source of novel patient care information and serves as a national point of reference for prostate carcinoma presentation, diagnosis, and staging. Cancer 2003;98:1169–78. © 2003 American Cancer Society. DOI 10.1002/cncr.11635 | en_US |
dc.format.extent | 105539 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Prostate carcinoma presentation, diagnosis, and staging | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan ; Dr. Montie has a financial and/or other relationship with Astra Zeneca and UroCor. | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan ; Fax: (734) 936-9127 ; Department of Urology, Taubman Health Care Center, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0330 | en_US |
dc.contributor.affiliationother | Commission on Cancer, American College of Surgeons, Chicago, Illinois | en_US |
dc.identifier.pmid | 12973840 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34379/1/11635_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.11635 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.